Answers are grounded in this paper and cite their sources.
The therapy of type 2 diabetes has advanced significantly with the introduction of the sodium–glucose cotransporter 2 (SGLT2) inhibitor class of medications, which show benefits beyond glucose control, such as blood pressure reduction, weight loss, and protection of the kidneys and heart. The newest medication in the SGLT2 inhibitor class to be licensed in India for the treatment of type 2 diabetes is remogliflozin etabonate (RE). With the unusual characteristics of being taken as a prodrug, having active metabolites, and having a short half-life that requires a twice-daily dose, RE is a strong and selective SGLT2 inhibitor. It is considered for its effectiveness and is well tolerated with fewer adverse effects. This case report discusses the development of pruritus in a patient following the initiation of remogliflozin therapy.
No takes yet. Share an insight, caveat, or question.
Athul et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: